[1]
|
梁艳霞, 樊茂蓉, 王冰, 赵媛, 马卉, 张子然, 丛晓东. 结缔组织病相关间质性肺病中医病因病机及治疗研究进展[J]. 中国医药导报, 2022, 19(15): 33-36.
|
[2]
|
卞大晨, 肖永龙, 刘布俊, 等. 结缔组织疾病相关性间质性肺病与特发性间质性肺炎比较研究[J]. 中国呼吸与危重监护杂志, 2014, 13(3): 263-267.
|
[3]
|
Fischer, A., Antoniou, K.M., Brown, K.K., et al. (2015) An Official European Respiratory Society/American Thoracic Society Research State-ment: Interstitial Pneumonia with Autoimmune Features. European Respiratory Journal, 46, 976-987. https://doi.org/10.1183/13993003.00150-2015
|
[4]
|
Jee, A.S., Adelstein, S., Bleasel, J., et al. (2017) Role of Au-toantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoim-mune Features (IPAF). Journal of Clinical Medicine, 6, 51.
https://doi.org/10.3390/jcm6050051
|
[5]
|
Jee, A.S., Sheehy, R., Hopkins, P., et al. (2021) Diagnosis and Manage-ment of Connective Tissue Disease-Associated Interstitial Lung Disease in Australia and New Zealand: A Position Statement from the Thoracic Society of Australia and New Zealand. Respirology, 26, 23-51. https://doi.org/10.1111/resp.13977
|
[6]
|
Fernandes, L., Nasser, M., Ahmad, K., et al. (2019) Interstitial Pneumonia with Autoimmune Features (IPAF). Frontiers in Medicine (Lausanne), 6, 209. https://doi.org/10.3389/fmed.2019.00209
|
[7]
|
黄慧, 胡立星, 徐作君. 具有自身免疫特征的间质性肺炎的命名及诊断标准(摘译)——欧洲呼吸病学会和美国胸科学会官方共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 433-437.
|
[8]
|
赛晓焱, 蔡后荣. 具有自身免疫特征的间质性肺炎研究进展[J]. 中国呼吸与危重监护杂志, 2017, 16(3): 300-304.
|
[9]
|
原庆, 刘建, 郭丽娅, 等. 具有自身免疫特征的间质性肺炎患者中西医临床信息分析[J]. 中国中医基础医学杂志, 2018, 24(8): 1106-1108.
|
[10]
|
郑雅文, 高鑫, 苗裔, 等. 具有自身免疫特征的间质性肺炎的临床特征及转归[J]. 河南医学研究, 2020, 29(35): 6529-6532.
|
[11]
|
Chartrand, S., Lee, J.S., Swigris, J.J., Stanchev, L. and Fischer, A. (2019) Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 197, 709-713.
https://doi.org/10.1007/s00408-019-00276-7
|
[12]
|
Ahmad, K., Barba, T., Gamondes, D., Ginoux, M., et al. (2017) Interstitial Pneumonia with Autoimmune Features: Clinical, Radiologic, and Histological Characteristics and Outcome in a Series of 57 Patients. Respiratory Medicine, 123, 56-62. https://doi.org/10.1016/j.rmed.2016.10.017
|
[13]
|
Oldham, J.M., Adegunsoye, A., Valenzi, E., et al. (2016) Characterisation of Patients with Interstitial Neumonia with Autoimmune Features. European Respiratory Journal, 47, 1767-1775. https://doi.org/10.1183/13993003.01565-2015
|
[14]
|
Ferri, C., Manfredi, A., Sebastiani, M., et al. (2016) Interstitial Pneumonia with Autoimmune Features and Undifferentiated Connective Tissue Disease: Our Interdisciplinary Rheumatology-Pneumology Experience, and Review of the Literature. Autoimmunity Reviews, 15, 61-70. https://doi.org/10.1016/j.autrev.2015.09.003
|
[15]
|
郭红敏. 不同结缔组织病肺间质病变(CTD-ILD)的临床特点及治疗效果[J]. 中国保健营养, 2016, 26(16): 136.
|
[16]
|
刘倩. 结缔组织病肺间质病变的临床特征及血清标志物的研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2015.
|
[17]
|
王宁. IPAF的临床特征及影响其死亡的危险因素分析[D]: [硕士学位论文]. 秦皇岛: 华北理工大学, 2021.
|
[18]
|
Cottin, V., Crestani, B., Cadranel, J., et al. (2017) French Practical Guidelines for the Diagnosis and Management of Idiopathic Pulmonary Fibrosis—2017 Update. Full-Length Version. Revue des Maladies Respiratoires, 34, 900-968.
https://doi.org/10.1016/j.rmr.2017.07.017
|
[19]
|
闫宏. 基于数据挖掘的姜良铎教授治疗结缔组织病相关肺间质疾病经验研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2021.
|
[20]
|
Wiertz, I.A., van Moorsel, C.H.M., Vorselaars, A.D.M., et al. (2018) Cyclophosphamide in Steroid Refractory Unclassifiable Idiopathic Interstitial Pneumo-nia and Interstitial Pneumonia with Autoimmune Features (IPAF). European Respiratory Journal, 51, Article ID: 1702519. https://doi.org/10.1183/13993003.02519-2017
|
[21]
|
Antoniou, K.M., Margaritopoulos, G., Economidou, F., et al. (2009) Pivotal Clinical Dilemmas in Collagen Vascular Diseases Associated with Interstitial Lung Involvement. European Respiratory Journal, 3, 882-896.
https://doi.org/10.1183/09031936.00152607
|
[22]
|
Tashkin, D.P., Roth, M.D., Clements, P.J., et al. (2016) Myco-phenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Random-ised Controlled, Double-Blind, Parallel Group Trial. The Lancet Respiratory Medicine, 4, 708-719. https://doi.org/10.1016/S2213-2600(16)30152-7
|
[23]
|
McCoy, S.S., Mukadam, Z., Meyer, K.C., et al. (2018) My-cophenolate Therapy in Interstitial Pneumonia with Autoimmune Features: A Cohort Study. Therapeutics and Clinical Risk Management, 14, 2171-2181.
https://doi.org/10.2147/TCRM.S173154
|
[24]
|
Distler, O., Highland, K.B., Gahlemann, M., et al. (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. The New England Journal of Medicine, 380, 2518-2528. https://doi.org/10.1056/NEJMoa1903076
|
[25]
|
Solomon, J.J., Danoff, S.K., Goldberg, H.J., et al. (2019) The De-sign and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy, 36, 3279-3287. https://doi.org/10.1007/s12325-019-01086-2
|
[26]
|
张萌. 吡非尼酮对特发性间质性肺炎外周血清KL-6水平的影响[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2017.
|
[27]
|
Maher, T.M., Corte, T.J., Fischer, A., et al. (2020) Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine, 8, 147-157. https://doi.org/10.1016/S2213-2600(19)30341-8
|
[28]
|
赵书山, 王健. 自身免疫特征的间质性肺炎研究进展[J]. 浙江医学, 2020, 42(18): 2021-2024.
|
[29]
|
唐攀. 具有自身免疫特征的间质性肺炎KL-6、MMP-7和CCL-18表达水平检测及临床特征分析[D]: [硕士学位论文]. 宁波: 宁波大学, 2020.
|
[30]
|
Luppi, F. and Wells, A.U. (2016) In-terstitial Pneumonitis with Autoimmune Features (IPAF): A Work in Progress. European Respiratory Journal, 47, 1622-1624. https://doi.org/10.1183/13993003.00690-2016
|